Keywords
Last Name
Institution

Jordan J. Elm

Title
InstitutionMedical University of South Carolina
DepartmentPublic Health Sciences
AddressP.O. Box MSC 835
305N
Cannon Place - 135 Cannon St.
Phone843-876-1605
Fax843-876-1126
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Biffi A, Kuramatsu JB, Leasure A, Kamel H, Kourkoulis C, Schwab K, Ayres AM, Elm J, Gurol ME, Greenberg SM, Viswanathan A, Anderson CD, Schwab S, Rosand J, Testai FD, Woo D, Huttner HB, Sheth KN. Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage. Ann Neurol. 2017 Nov; 82(5):755-765. PMID: 29028130.
      View in: PubMed
    2. Broderick JP, Adeoye O, Elm J. Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. Stroke. 2017 07; 48(7):2007-2012. PMID: 28626052.
      View in: PubMed
    3. Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017 Jun 15; 377:137-143. PMID: 28477684.
      View in: PubMed
    4. Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127. PMID: 27911341.
      View in: PubMed
    5. Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord. 2016 Dec; 33:127-133. PMID: 27743701.
      View in: PubMed
    6. Augustine EF, Dorsey ER, Hauser RA, Elm JJ, Tilley BC, Kieburtz KK. Communicating with participants during the conduct of multi-center clinical trials. Clin Trials. 2016 Dec; 13(6):592-596. PMID: 27573636.
      View in: PubMed
    7. Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, Ostwaldt AC, Del Zoppo GJ, Simard JM, Jacobson S, Kimberly WT. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct; 15(11):1160-9. PMID: 27567243.
      View in: PubMed
    8. Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 05; 31(5):709-14. PMID: 27030249.
      View in: PubMed
    9. Sheth KN, Elm JJ, Beslow LA, Sze GK, Kimberly WT. Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design. Neurocrit Care. 2016 Feb; 24(1):132-9. PMID: 26268138.
      View in: PubMed
    10. Sheth KN, Simard JM, Elm J, Kronenberg G, Kunte H, Kimberly WT. Human Data Supporting Glyburide in Ischemic Stroke. Acta Neurochir Suppl. 2016; 121:13-8. PMID: 26463916.
      View in: PubMed
    11. Revuelta GJ, Embry A, Elm JJ, Gregory C, Delambo A, Kautz S, Hinson VK. Pilot study of atomoxetine in patients with Parkinson's disease and dopa-unresponsive Freezing of Gait. Transl Neurodegener. 2015; 4:24. PMID: 26693006; PMCID: PMC4676139.
    12. Chaisinanunkul N, Adeoye O, Lewis RJ, Grotta JC, Broderick J, Jovin TG, Nogueira RG, Elm JJ, Graves T, Berry S, Lees KR, Barreto AD, Saver JL. Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale. Stroke. 2015 Aug; 46(8):2238-43. PMID: 26138130; PMCID: PMC4519373.
    13. Parashos SA, Elm J, Boyd JT, Chou KL, Dai L, Mari Z, Morgan JC, Sudarsky L, Wielinski CL. Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale. J Parkinsons Dis. 2015; 5(1):67-73. PMID: 25311202; PMCID: PMC4478048.
    14. Bega D, Kim S, Zhang Y, Elm J, Schneider J, Hauser R, Fraser A, Simuni T. Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis. 2015; 5(4):773-82. PMID: 26639661.
      View in: PubMed
    15. Simon DK, Simuni T, Elm J, Clark-Matott J, Graebner AK, Baker L, Dunlop SR, Emborg M, Kamp C, Morgan JC, Ross GW, Sharma S, Ravina B. Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. J Parkinsons Dis. 2015; 5(4):731-6. PMID: 26444095.
      View in: PubMed
    16. Sheth KN, Kimberly WT, Elm JJ, Kent TA, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, del Zoppo G, Simard JM, Stern BJ, Mandava P. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014 Aug; 21(1):43-51. PMID: 24671831; PMCID: PMC4435684.
    17. Elm JJ, Palesch Y, Easton JD, Lindblad A, Barsan W, Silbergleit R, Conwit R, Dillon C, Farrant M, Battenhouse H, Perlmutter A, Johnston SC. Screen failure data in clinical trials: Are screening logs worth it? Clin Trials. 2014 Aug; 11(4):467-472. PMID: 24925082.
      View in: PubMed
    18. Kimberly WT, Battey TW, Pham L, Wu O, Yoo AJ, Furie KL, Singhal AB, Elm JJ, Stern BJ, Sheth KN. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014 Apr; 20(2):193-201. PMID: 24072459.
      View in: PubMed
    19. Constantinescu R, Elm J, Auinger P, Sharma S, Augustine EF, Khadim L, Kieburtz K. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord. 2014 Feb; 29(2):263-5. PMID: 24323565; PMCID: PMC4375545.
    20. Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, Simard JM, Stern BJ. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke. 2014 Jan; 45(1):281-3. PMID: 24193798; PMCID: PMC4235339.
    21. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, Fountain N, Jones E, Lowenstein D, Shinnar S, Silbergleit R, Treiman D, Trinka E, Kapur J. The established status epilepticus trial 2013. Epilepsia. 2013 Sep; 54 Suppl 6:89-92. PMID: 24001084; PMCID: PMC4048827.
    22. Johnston SC, Easton JD, Farrant M, Barsan W, Battenhouse H, Conwit R, Dillon C, Elm J, Lindblad A, Morgenstern L, Poisson SN, Palesch Y. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013 Aug; 8(6):479-83. PMID: 23879752; PMCID: PMC4412261.
    23. Connor JT, Elm JJ, Broglio KR. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013 Aug; 66(8 Suppl):S130-7. PMID: 23849147; PMCID: PMC3743558.
    24. Luo S, Lawson AB, He B, Elm JJ, Tilley BC. Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial. Stat Methods Med Res. 2016 Apr; 25(2):821-37. PMID: 23242384; PMCID: PMC3883900.
    25. Elm JJ. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct; 27(12):1513-21. PMID: 23079770.
      View in: PubMed
    26. Voss TS, Elm JJ, Wielinski CL, Aminoff MJ, Bandyopadhyay D, Chou KL, Sudarsky LR, Tilley BC. Fall frequency and risk assessment in early Parkinson's disease. Parkinsonism Relat Disord. 2012 Aug; 18(7):837-41. PMID: 22542094; PMCID: PMC3424355.
    27. Tilley BC, Mainous AG, Elm JJ, Pickelsimer E, Soderstrom LH, Ford ME, Diaz VA, Siminoff LA, Burau K, Smith DW. A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy. Clin Trials. 2012 Apr; 9(2):188-97. PMID: 22496398; PMCID: PMC4399486.
    28. Meurer WJ, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, Connor J, Durkalski V, Elm J, Zhao W, Frederiksen S, Silbergleit R, Palesch Y, Berry DA, Barsan WG. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct; 60(4):451-7. PMID: 22424650; PMCID: PMC3557826.
    29. Yoo AJ, Sheth KN, Kimberly WT, Chaudhry ZA, Elm JJ, Jacobson S, Davis SM, Donnan GA, Albers GW, Stern BJ, González RG. Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke. J Stroke Cerebrovasc Dis. 2013 Aug; 22(6):742-9. PMID: 22325573; PMCID: PMC3529850.
    30. Elm JJ, Palesch YY, Koch GG, Hinson V, Ravina B, Zhao W. Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72. PMID: 22651113; PMCID: PMC3770292.
    31. Bonilha L, Elm JJ, Edwards JC, Morgan PS, Hicks C, Lozar C, Rumboldt Z, Roberts DR, Rorden C, Eckert MA. How common is brain atrophy in patients with medial temporal lobe epilepsy? Epilepsia. 2010 Sep; 51(9):1774-9. PMID: 20412283.
      View in: PubMed
    32. Schneider JS, Elm JJ, Parashos SA, Ravina BM, Galpern WR. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Parkinsonism Relat Disord. 2010 Sep; 16(8):507-12. PMID: 20598621; PMCID: PMC2930040.
    33. Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, Elm J, Ravina B, Bergmann KJ, Kieburtz K. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9. PMID: 19514076; PMCID: PMC2813508.
    34. Ravina B, Elm J, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11. PMID: 19412939; PMCID: PMC2788307.
    35. Ravina B, Swearingen C, Elm J, Kamp C, Kieburtz K, Kim SY. Long term understanding of study information in research participants with Parkinson's disease. Parkinsonism Relat Disord. 2010 Jan; 16(1):60-3. PMID: 19501011; PMCID: PMC2817997.
    36. Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7. PMID: 17581943; PMCID: PMC2031220.
    37. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007 Apr 30; 22(6):822-7. PMID: 17357141.
      View in: PubMed
    38. Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33. PMID: 16534099.
      View in: PubMed
    39. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203. PMID: 15668964.
      View in: PubMed
    40. Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18. PMID: 16422311.
      View in: PubMed
    Elm's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _